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A PRESSING medical question, which is as yet unanswered, is that of the role
ofradiotherapy in the management ofinoperable cancer ofthe lung. That opinions
regarding the beneficial effects of radiotherapy differ widely is confirmed by the
varying approach to treatment in different centres. Advances in thoracic surgery
have brought in their wake a considerable deterioration of the type of case
referred for radiotherapy. In addition, some radiotherapy centres do not accept
cases of carcinoma of the lung for treatment unless they present with signs of
superior vena caval syndrome, haemoptysis, dysphagia or pain.
The initial policy of both thoracic surgeons and physicians is often either
surgery or nothing ", and radiotherapy is used only when patients are in ex-
tremis, requiring some symptomatic relief. Frequently chemotherapy is given
in preference to radiotherapy, even in cases belonging to histological groups not
sensitive to chemotherapy. With the advent of more powerful machines the ques-
tion of the usefulness of radiotherapy in bronchial carcinoma has been reopened,
as is shown by several controlled trials which are under way. Whatever the terms
ofthese trials, it is desirable to assess the value ofseveral radiotherapy techniques
at 200-250 kV, and not only those that are conventional. The present paper on
the results of treatment with X-ray sieve therapy (Jolles, 1949, 1952, 1953, 1960)
claims that this approach is better than more conventional methods at 200-250 kV.
This is of importance if future claims of supervoltage therapy are to be assessed
fairly, when the results obtained with lower voltage techniques should be
available.
The survival rates after radiotherapy throw some light on the advisability of
so-called radical radiotherapy, but the clinical management of patients with this
dreaded disease suggests that the question of how the patient lives before death
overtakes him is a most important one. In the assessment of results it is the
symptomatic improvement of the patient treated by radiotherapy that indicates
any benefit received.
Indicationsfor sieve therapy
Two common findings indicate the need for the adoption of sieve therapy.
(1) The site. The vicinity of vital organs apart from those vital structures
already involved in the neoplastic process, and the liability of lung tissues to
radiation fibrosis and secondary infection indicate that conventional methods of
treatment are beset with great difficulties. If radiation effects on normal tissues
are to be diminished new approaches must be tried.
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(2) The extent ofthe disease. In about 80 per cent of cases, wide involvement
ofthe regional lymph nodes is found at the commencement oftreatment. Volumes
with a long axis not less than 12 to 15 cm. usually have to be included in the
irradiation field. In the majority of patients the treatment of small volumes is
futile. After a thoracotomy has been performed, the volume to be treated is still
larger, emphasising the need for large field therapy.
METHOD
The sieve or grid method satisfies these two requirements. Fractionation of
radiation in space as well as in time allows the delivery of large amounts of
radiation in depth without overloading the skin.
The principle of the method is that, with a lead chess-board sieve, portions
of the tumour surface, 0-5-1 0 cm. square, are exposed to radiation while other
portions of similar area are protected, so that important structures remain un-
damaged and can take part in repair. For superficial tumours, and on occasion
for deep seated tumours, the position of the radio-opaque and transparent areas
is reversed and a second course oftreatment is given, to the previously unexposed
areas. The already treated areas are thus protected and their recovery is not
hindered.
Sieves with an open to protected area 50: 50 ratio were used in the North-
ampton series, while sieves with 50: 50, 40: 60 and 34: 60 were applied in cases
reported from other centres (v.q.). In a few cases sieves of 34: 60 ratio were
used while approximately two-thirds were treated with 40: 60 sieves. The ease
with which complementary sieves can be used in subsequent series of treatment,
makes the 50: 50 sieves, though not so easy to manufacture, on the whole
preferable.
The sieve openings were 0*8-1*0 cm. in diameter. The kilovoltage was 200-250,
and the H.V.L. in the great majority ofcases was 2 mm. Cu. The overall treatment
time varied from 4-6 weeks, but in some cases after an interval of 6-8 weeks a
second series of treatments was given.
The daily dose varied between 500-800 r and on occasions 1000 r on either
one or two fields were given throughout the treatment series.
The depth dose was assessed as " average " or the mean of the " maximum
i.e. of the dose under open areas and the " minimum " in the shaded portions.
Mean tumour doses ranging from 2500 r to 4500 r were given in the Northampton
series.
RESULTS
1976 cases of carcinoma of the lung were registered in the Oxford Regional
Hospital Board Area during the years 1954-1957 inclusive. This Region has a
population of 1-5 million and is served by three radiotherapy departments situated
in Northampton, Oxford and Reading. In the period under review, 441 cases of
carcinoma of the lung were treated with radiation to the primary, 249 with
surgery, 100 with various forms of treatment such as nitrogen mustard or com-
bined surgery and radiotherapy, while 1186 received no treatment whatsoever.
The majority of the latter cases was never referred for radiotherapy and some
had an exploratory thoracotomy. All patients treated by the sieve method were
selected only in that the disease was always very advanced.
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Of the 441 cases treated with radiation 140 were dealt with at Northampton
(117 sieve, 23 conventional), 212 at Oxford (134 conventional and 78 sieve or
combined sieve plus conventional) and 89 at Reading (conventional).
The general condition of the 23 patients treated with conventional techniques
in the Northampton series was better and their disease was considered less ad-
vanced than that of those treated with the sieve technique.
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In Fig. 1 are shown the length ofhistory and survival in 117 cases treated with
the sieve technique at Northampton. Nine cases which did not complete treat-
ment are included. "A" denotes cases with adenocarcinoma. The bottom 8 cases
were alive when the histogram was drawn.
A symptomatic improvement was noted in almost all cases from the beginning
of treatment, which was very well tolerated. The skin reaction was not brisk;
a mosaic of small areas of moist disepithelisation, which healed within two weeks
leaving a pigmentation, was all that was noted on the anterior chest field after
doses from 10,000-12,500 r over a period of 4-5 weeks. Only dry desquamation
and a few oozing spots were produced by 9,000 r on the patients' backs. This, in
patientswith an A.P. diameter of 21 cm., gave at 2.25 mm. Cu. H.V.L. a maximum
depth dose of 4600 r, minimum 2600 r, average 3600 r. When an exploratory
20
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thoracotomy had been performed previously a third sieve field was added on
the lateral chest wall (5000-6000r). Postradiation fibrosis of the lung was
noted in only two cases.
The subdivision of the cases into histological groups in the 117 Northampton
series (Fig. 2) and of 287 cases from another centre has revealed that the survival
ofthe group of squamous cell carcinoma is slightly longer than in the other groups.
In a further subdivision of a series of 404 cases from 2 centres into the "over"
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FIG. 2.-The subdivision of the cases into histological groups in the Northampton series.
and "under" 60 years of age groups, the former appeared to be doing slightly
better and the length of history before treatment has been greater in the over 60
group; this was also found in the German series of cases.
In Table I are shown the survival times of the cases treated with the two
techniques.
In Table II are set out the survival times of patients who lived for more than
3 years after treatment.
Generally it is not the length of survival that matters but the quality of the
improvement that is brought about by the treatment. With this in view it was
thought that it might be useful to evaluate the clinical results using the criteria
adopted by Karnofsky et al. (1951) and Mitchell (1960), in their respective studies
of the results of treatment with nitrogen mustard, and the role of Synkavit as a
-
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TABLE I.-Oxford Regional Board Area, Carcinoma of the Lung
1954-1957 Inclusive
Number (September 1, 1960) Alive at:
Method of of - A
treatment cases 3 months 6 12 24 36
Radiotherapy:
Sieve: Northampton. 117 . 89 (76%) 61 (52%) 21 (18%) 7 (6%) 6 (5%)
Sieve: all cases 195 138 (71%) 102 (52°%) 44 (23%) 8 (4%) 6 (3%)
Conventional fields 246 134 (55%) 73 (30%) 22 (9%) 8 (3%) 2 (0-8%)
Surgery* . . 249
Various . 100 59 (59%) 40 (40%) 21 (21%) 8 (8%) 2 (2%)
No treatment . 1186 . 450 (38%) 230 (19-5%) 105 (9%) 22 (2%) 4 (0-34%)
* Follow-up data not yet complete.
TABLE II.-The Survival Times of Patients who Livedfor More than
3 Years after Treatment
Sieve fields Conventional fields -5-<--5
Survival Dose Survival Dose
in montbs Histology average in months Histology average
Alive
36 9 pos. + High dose 36 Anaplastic High dose
44 Sputum pos. + 3000 r 36 Squamous cell ca.
56 . Nil 3600fr 36 . pos. +
70* . Squamous cell ca. 3600 r 36 . Nil
72 . Squamous cell ca. 6000 r
Dead
36 . Nil 3000 r
36 ? pos. + High dose
40 Squamous cell ca. ,, ,, 58 Nil High dose
43 . Nil ,.
44 . Sputum pos. + 2875 r
56 . ,, ,, ,, 4375 e
* This patient who received sieve treatment from 21/12/54 to 21/1/55 for a poorly differentiated
squamous cell carcinoma in the right upper lobe bronchus, developed 68 months later, another
tumour of the same histological pattern in the left lung, for which he was also treated with sieve
therapy. He was alive and fairly well at the end of April, 1961.
sensitizer in radiotherapy of bronchial carcinoma. The subjective and objective
improvement shown by the relief of symptoms and measurable regression of
lesions (X-ray films, etc.) set out in the " Performance Status " which attempts
to measure the patients' ability to continue useful work, etc., was studied in the
Northampton cases. The period of improvement and relative well-being repre-
sented approximately 75 per cent of the survival time after treatment.
In order to substantiate the conclusions regarding the role of sieve therapy in
bronchial carcinoma a questionnaire was sent to several radiotherapy centres in
the United Kingdom and abroad. Collaboration, for which the author is greatly
indebted, was ensured from 8 centres (Professor Sir Brian Windeyer and Miss
M. D. Snelling, Middlesex Hospital, London; Professor R. Paterson, Christie
Hospital, Manchester; Dr. A. G. C. Taylor, Royal South Hants Hospital,
Southampton; Dr. P. Kroker, Evangel. Krankenhaus, Essen, and Dr. W. PfeiferSIEVE THERAPY OF BRONCHIAL CARCINOMA
and Dr. K. Seidel, Oldenburgisches Landeskrankenhaus, Sanderbusch in Germany,
and of Professor H. Kaneda, Shinshu University, Kyoto, Japan). Including 14
cases reported by Hohl in Zurich (1953) and 110 cases by Haubrich and Thurn
(1957) and the above discussed cases from Northampton, as well as 78 cases treated
with the sieve or sieve plus conventional techniques by Dr. F. Ellis, Churchill
Hospital, Oxford, a total of 942 cases of bronchial carcinomas treated with the
sieve was collected. Of these, 60 cases comprising mostly patients with superior
vena caval syndrome were treated with a single massive dose of 4-5000 r through
a sieve. In the centre in which these patients were treated it was thought that
this technique gave worthwhile palliation. A further 86 cases received sieve
therapy after surgery, either post-operatively or for recurrences, and will be dis-
cussed later.
In the group of 677 British sieve cases the ratio of male to female was 10: 1.
There were 150 squamous celled carcinomas, 139 anaplastic tumours, 12 adeno-
carcinomas and 316 were classified as " no histology ". In the " no histology "
group were included a few positive malignant tumours which were not typed, and
also a number of sputum-positive cases.
In Table III the overall results of treatment with the sieve method (inclusive
of the Northampton and Oxford cases) are compared with cases treated with
conventional methods.
TABLE III.-The Overall Results of Treatment with the Sieve Method
Compared with Conventional Methods
Number Alive at
of
A
Method cases 6 inonths 12 months 24 months 36 months
Sieve: Northampton . 117 . 61 (52%) 21 (18%) 7 (6%) 6 (5%)
All centres . 769 . 378 (49%) 158 (21%) 30 (4%) 11 (1.4%)
Conventional fields: Four centres 483 . 138 (28.5%) 46 (9 5%) 15 (3%) 6 (1 2%)
Fig. 3 shows the survival of patients who received X-ray sieve therapy after
pneumonectomy, lobectomy and exploratory thoracotomy. The time interval
between the operation and radiotherapy, and the survival after the radiotherapy
are shown for each case. It can be seen that a good degree of palliation can be
achieved by sieve therapy post-operatively.
DISCUSSION
The published results of the treatment of bronchial carcinomas with X-rays
in the 200-250 kV range make very sober reading. Average survival of 4 months
after treatment in a large series of cases have been recorded by many authors
(Fulton, 1949; Schulz, 1957).
It can be seen from the foregoing that the sieve method often gave better
results than conventional techniques. The objective and subjective clinical
improvement, achieved at very little expense to the patient in terms of untoward
radiation reaction, extra morbidity and post-radiation lung changes, shows
clearly the superiority of a method based on fractionation in space as well as in
time.
When it is realised that the series presented in this paper consisted of very
advanced cases and that attempts at a " cure " by intensive methods of radio-
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therapy was deemed worthwhile only in very few, theni the conclusions drawn
seems quite justified. The operability rate in bronchial carcinoma does not exceed
15 per cent of all cases and the great majority of cases referred for radiotherapy
are well beyond the scope ofany radical attempt at cure. It can be argued whether
there is any justification for submitting patients with advanced carcinoma of the
lung to treatments which will produce only small gains in terms of survival, at
the expense of suffering in a great proportion of cases who are beyond practical
radiotherapy.
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Fim. 3.-The survival of patients who received X-ray sieve therapy after pneumonectomy,
lobectomy and exploratory thoracotomy.
The selection of cases for various types of treatment makes a comparison of
published results of little value, and worthwhile conclusions cannot be drawn from
statistical reviews unless these present the fate of all cases of bronchial carcinoma
registered in the particular area. However, there should be no doubt that we must
at all costs avoid causing by radiation any deterioration in the patient's condition.
Treatment -in selected cases with supervoltage machines does not produce much
better results (Hohl, 1953; Haas, Harvey and Melchor, 1957). Morrison and
Deeley (1960) reported a survival rate of 6 per cent at 3 years in a selected series
of cases treated by an 8 MeV linear accelerator. These results do not yet justify
any change in our decision as regards the main aims of treatment, either a radical
attempt at cure, or palliation.
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The claim that the sieve technique has an important place in the treatment
of advanced bronchial carcinoma is well supported. It is also worthwhile stressing
that with the sieve technique it is possible to deliver a high dose of radiation in
depth over the large regions which have to be covered in most patients with
bronchial carcinoma, without causing damage to lung and other tissues.
SUMMARY
A survey of 117 cases of bronchial carcinoma treated with the sieve method at
Northampton has been made. The details of the technique are given and the
results compared with those oftwo groups of cases treated in the Oxford Regional
Board Area and various Departments throughout the world.
It is shown that the sieve technique has given better results than the conven-
tional methods. Patients improve subjectively and objectively, without any un-
toward radiation effects. In addition, there are advantages of a biological and
technical nature which indicate that sieve therapy has a role to play in the radio-
therapy of bronchial carcinoma.
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